Please use this identifier to cite or link to this item:
10.2147/opth.s8011
Title: | Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension |
Authors: | Teus, Miguel A. Miglior, Stefano Laganovska, Guna Volksone, Lasma Romanowska-Dixon, Bozena Gos, Roman Holló, Gábor |
Keywords: | Dorzolamide;Fixed combination;Glaucoma;IOP-lowering therapy;Timolol;Travoprost;3.2 Clinical medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;Ophthalmology |
Issue Date: | 2009 |
Citation: | Teus , M A , Miglior , S , Laganovska , G , Volksone , L , Romanowska-Dixon , B , Gos , R & Holló , G 2009 , ' Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension ' , Clinical Ophthalmology , vol. 3 , no. 1 , pp. 629-636 . https://doi.org/10.2147/opth.s8011 |
Abstract: | Purpose: To compare the intraocular pressure- (IOP-) lowering efficacy of fixed combinations travoprost 0.004%/timolol 0.5% and dorzolamide 2%/timolol 0.5% in patients with ocular hypertension or open-angle glaucoma. Methods: In this prospective, multicenter, double-masked, randomized clinical trial, 319 qualifying patients received either travoprost/timolol once daily in the morning (n = 157) or dorzolamide/timolol twice daily (n = 162). IOP was assessed morning and evening at 2 and 6 weeks. The primary outcome measure was mean diurnal IOP. Results: Baseline mean IOP values were similar between groups. Mean pooled diurnal IOP was significantly lower in the travoprost/timolol group (16.5 mmHg ± 0.23) than in the dorzolamide/timolol group (17.3 mmHg ± 0.23; P = 0.011). Mean IOP was significantly lower in the travoprost/timolol group compared to the dorzolamide/timolol group at the 9 AM time point both at Week 2 (P = 0.006) and Week 6 (P = 0.002). The travoprost/timolol combination produced mean IOP reductions from baseline of 35.3% to 38.5%, while the dorzolamide/timolol combination produced mean IOP reductions from baseline of 32.5% to 34.5%. Conclusions: The fixed combination travoprost 0.004%/timolol 0.5% dosed once daily in the morning demonstrated superior mean diurnal IOP-lowering efficacy compared to dorzolamide 2%/timolol 0.5% dosed twice daily in patients with ocular hypertension or open-angle glaucoma. |
DOI: | 10.2147/opth.s8011 |
ISSN: | 1177-5467 |
Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Efficacy_and_safety_of_travoprost.pdf | 219.57 kB | Adobe PDF | View/Open![]() |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.